Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALICE in high-tumor-burden hepatocellular carcinoma
2024-514912-28-00Phase 3Suspended
- Sponsor
- Unicancer
- Start
- Oct 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tiragolumab, gemcitabine and oxaliplatin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Unicancer. Primary endpoints: Objective response rate and Overall survival. Started Oct 2025; status: suspended.
02
Drugs
durvalumabtiragolumabgemcitabineoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-514912-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514912-28-00.